1. SUB-TYPE OF MDS: All subtypes of MDS
2. SEVERITY OF MDS: High Risk MDS and Acute myeloid leukaemia.
3. NAME OF DRUG: CCS-1477 . CCS-1477 is a drug in oral form that blocks certain enzymes that are needed to encourage the expression of genes that drive cancer. It also causes the destruction of some proteins that are important in cancer cell development.
   
4. Aims and benefits: This Phase I/IIa study investigates the safety, tolerability and activity of CCS-1477 in the body.
5. Primary outcome: To identify adverse events related to the treatment.
6. Secondary outcome: To determine the rate of response and duration of response to the treatment.

1. Basic inclusion criteria:
   • Patients with relapsed/refractory AML or high risk MDS patients who previously received standard therapy.
   • ECOG performance status of ≤ 2.
2. Basic exclusion criteria:
   • Patients with severe/uncontrolled systemic disease.
   • Unresolved reversible toxicities.
3. Trial sites/locations and name of physician in charge of trial (none are currently recruiting):
   • University Hospital of Wales, Cardiff, Contact: Steven Knapper
   • Leicester Royal Infirmary, Leicester, Contact: Harriet Walter
   • The Christie Hospital, Manchester, Contact: Tim Somervaille
   • Cancer and Haematology Centre, Oxford, Contact: Paresh Vyas

If you think this information is relevant to you, please discuss it with your own physician.